000			02931nam a22003617a 4500
008			240723s20242024 xxu||||| |||| 00| 0 eng d
024			_aPMC10896412 [pmc]
040			_aOvid MEDLINE(R)
099			_a38410488
245			_aTiming of Regadenoson-induced Peak Hyperemia and the Effects on Coronary Flow Reserve.
251			_aMedRxiv : the Preprint Server for Health Sciences. 2024 Jan 16
252			_amedRxiv. 2024 Jan 16
253			_amedRxiv : the preprint server for health sciences
260			_c2024
260			_p2024 Jan 16
260			_fFY2024
265			_sepublish
265			_tPubMed-not-MEDLINE
520			_aBackground: Regadenoson is used to induce hyperemia in cardiac imaging, facilitating diagnosis of ischemia and assessment of coronary flow reserve (CFR). While the regadenoson package insert recommends administration of radionuclide tracer 10-20 seconds after injection, peak hyperemia has been observed at approximately 100 seconds after injection in healthy volunteers undergoing cardiovascular magnetic resonance imaging (CMR). It is unclear when peak hyperemia occurs in a patient population.
520			_aConclusion: Imaging at 90 seconds following regadenoson injection is the optimal approach to capture peak hyperemia. Imaging at 30 seconds, which is more aligned with the package insert recommendation, would yield an underestimate of CFR and confound assessment of microvascular dysfunction.
520			_aMethods: Healthy volunteers (n=15) and patients (n=25) underwent stress CMR, including phase-contrast imaging of the coronary sinus at rest and multiple timepoints after 0.4 mg regadenoson injection. Coronary sinus flow (ml/min) was divided by resting values to yield CFR. Smoothed, time-resolved curves for CFR were generated with pointwise 95% confidence intervals.
520			_aObjectives: The goal of this study was to determine time to peak hyperemia after regadenoson injection in healthy volunteers and patients, and whether the recommended image timing in the package insert underestimates CFR.
520			_aResults: CFR between 60 and 120 seconds was significantly higher than CFR at 30 seconds after regadenoson injection (p < 0.05) as shown by non-overlapping 95% confidence intervals for both healthy volunteers (30 s, [2.8, 3.4]; 60 s, [3.8, 4.4]; 90 s, [4.1, 4.7]; 120 s, [3.6, 4.3]) and patients (30 s, [2.1, 2.5]; 60 s, [2.6, 3.1]; 90 s, [2.7, 3.2]; 120 s, [2.5, 3.1]).
546			_aEnglish
650			_zAutomated
651			_aMedStar Heart & Vascular Institute
657			_aPreprint
700			_aBarac, Ana _bMHVI
700			_aWeissman, Gaby _bMHVI
790			_aKattapuram N, Shadman S, Morgan EE, Benton C, Awojoodu S, Kim DY, Ramos J, Barac A, Bandettini WP, Kellman P, Weissman G, Carlsson M
856			_uhttps://dx.doi.org/10.1101/2024.01.15.23300449 _zhttps://dx.doi.org/10.1101/2024.01.15.23300449
942			_cART _dArticle
999			_c14281 _d14281